Dissemin is shutting down on January 1st, 2025

Published in

Lippincott, Williams & Wilkins, AIDS, 4(23), p. 534-538, 2009

DOI: 10.1097/qad.0b013e3283262a8d

Links

Tools

Export citation

Search in Google Scholar

Clinical course of classic Kaposiʼs sarcoma in HIV-negative patients treated with the HIV protease inhibitor indinavir:

Journal article published in 2009 by G. Barillari, Paolo Monini, G. Moracci, L. Carratelli, G. Gatti, Cecilia Sgadari, L. Brambilla, M. Brambati, S. Ferrucci ORCID, Maria Gabriella Grosso, O. De Pità, Pilla, Stefania Bellino, A. Di Carlo, M. Giuliani and other authors.
This paper was not found in any repository, but could be made available legally by the author.
This paper was not found in any repository, but could be made available legally by the author.

Full text: Unavailable

Green circle
Preprint: archiving allowed
Upload
Orange circle
Postprint: archiving restricted
Upload
Red circle
Published version: archiving forbidden
Policy details
Data provided by SHERPA/RoMEO

Abstract

HIV protease inhibitors have been shown to exert antiangiogenic and antitumor actions independently from their antiretroviral effect. Based on these studies, HIV-seronegative patients with classic Kaposi's sarcoma were treated with indinavir and followed for clinical evolution, drug pharmacokinetics and Kaposi's sarcoma biomarkers. A favorable clinical course was associated with high drug plasma levels, reduced production of basic fibroblast growth factor, lower numbers of circulating endothelial cells, and a decrease in antibody titers against human herpesvirus 8.